Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder

Area of Science:

• Pediatric Psychiatry
• Pharmacogenetics
• Neuroscience

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for pediatric obsessive-compulsive disorder (OCD).
• SSRIs are typically well-tolerated in pediatric patients.
• Understanding genetic factors influencing SSRI response is crucial for optimizing treatment.

Observation:

• Three pediatric patients with OCD developed behavioral disinhibition while treated with fluvoxamine.
• This adverse event occurred within the context of outpatient clinic visits.
• The observation highlights a potential, albeit rare, side effect of SSRI treatment in this population.

Findings:

• Behavioral disinhibition was observed in 3 out of 51 pediatric OCD patients treated with fluvoxamine.
• The cases suggest a possible link between fluvoxamine and behavioral changes in susceptible individuals.
• Pharmacogenetic testing for CYP2D6 and CYP2C19 may be relevant for predicting and managing such reactions.

Implications:

• The findings underscore the importance of monitoring for behavioral changes during SSRI treatment in children.
• CYP2D6 and CYP2C19 pharmacogenetic testing could aid in personalizing SSRI therapy for pediatric OCD.
• Further research is warranted to elucidate the mechanisms underlying SSRI-induced behavioral disinhibition in pediatric populations.